Femasys (NASDAQ:FEMY) announced that the U.S. FDA approved its modular premarket approval submission approach for FemBloc, the company’s investigational non-surgical permanent birth control technology.
Gennadiy Goldberg, TD Securities head of US rates strategy, says interest rate hikes by the Federal Reserve could help flatten the yield curve. But he believes the Fed is going to try and hold rates steady. He speaks on "Bloomberg Surveillance."
Merck and Moderna announced positive results from a large late-stage trial of their personalized mRNA cancer vaccine, which significantly reduced the recurrence of melanoma, the deadliest form of skin cancer. Madison Muller reports on "Bloomberg Open Interest."
Kiora Pharmaceuticals (NASDAQ:KPRX) licensed South Korean development and commercialization rights for its retinal therapy KIO-301 in ophthalmic indications to Chong Kun Dang Pharmaceutical (CKD).
James Bullard, former president of the St. Louis Fed and dean of Purdue's Mitch Daniels School of Business, says raising interest rates in September isn't too bad of an idea for the Federal Reserve. He speaks on "Bloomberg Surveillance."
Biodexa (NASDAQ:BDRX) announced that 87 of a planned 168 subjects have been enrolled in its registrational Phase 3 Serenta trial evaluating eRapa in Familial Adenomatous Polyposis (FAP).
Cosmos Health (NASDAQ:COSM) reported record second-quarter 2026 revenue of $18.99 million, up 28.8% year over year, with first-half revenue increasing 29.7% to $36.91 million.
Top Wealth Group Holding (NASDAQ:TWG) reported unaudited first-half 2026 revenue of $6.1 million, up 48% from $4.2 million a year earlier, driven mainly by expansion of its premium wine distribution business.
Teva Pharmaceuticals (NYSE:TEVA) announced that the U.S. FDA accepted its New Drug Application for ecopipam (EBS-101) and granted Priority Review for pediatric Tourette syndrome.
The US Department of the Treasury announced it will at least double the maximum size of its liquidity support buyback operations for longer-dated nominal coupon securities to at least $4 billion per operation, effective September 9, 2026. Michael McKee reports on Bloomberg Television.
Intelligent Bio Solutions (NASDAQ:INBS) reported fiscal 2026 revenue of $4.2 million, up 38% year over year, driven by growth in its installed reader base and consumable cartridge sales.
Chemomab Therapeutics (NASDAQ:CMMB) reported second-quarter 2026 results and progress on its proposed all-stock merger with Scipher Medicine, with Chemomab shareholders expected to own about 32% of a combined company valued at $150 million.
